PERSONALIZED MEDICINE – ARE WE THERE YET ? HIGHLIGHTS FROM THE SOCIETY OF MEDICINES

[1]  M. Petri,et al.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[2]  M. Buyse,et al.  Adjuvant Trastuzumab in HER 2-Positive Breast Cancer , 2011 .

[3]  Robert J. Williams,et al.  Collaborative approaches to anticancer drug discovery and development: a Cancer Research UK perspective. , 2012, Drug discovery today.

[4]  Jenny Taylor,et al.  Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. , 2012, Blood.

[5]  Peter Donnelly,et al.  Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas , 2013, Nature Genetics.

[6]  J. Bird,et al.  Mepolizumab for Severe Eosinophilic Asthma (DREAM): A Multicentre, Double-Blind, Placebo-Controlled Trial , 2013, Pediatrics.

[7]  A national platform for molecular diagnostics: Results of the Cancer Research UK Stratified Medicine Programme , 2014 .

[8]  F. Couch,et al.  Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer , 2014, Journal of the National Cancer Institute.

[9]  Peter Donnelly,et al.  Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis , 2014, Human molecular genetics.

[10]  R. Kurzrock,et al.  HER2 aberrations in cancer: implications for therapy. , 2014, Cancer treatment reviews.